Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinqiaosan + maxingganshitang is a combination of two foundational Traditional Chinese Medicine (TCM) formulas used for the treatment of acute respiratory infections. Yinqiaosan, originally described in the *Wen Bing Tiao Bian*, is composed of herbs like Lonicerae Japonicae Flos and Forsythiae Fructus, primarily aimed at resolving exterior wind-heat syndromes. Maxingganshitang, from the *Shang Han Lun*, consists of Ephedrae Herba, Armeniacae Semen Amarum, Gypsum Fibrosum, and Glycyrrhizae Radix et Rhizoma, and is traditionally used to clear lung heat and relieve cough and wheezing. Together, this combination is frequently prescribed for viral pneumonia, influenza, and COVID-19. Its pharmacological effects include broad-spectrum antiviral activity, significant anti-inflammatory properties through the inhibition of the NF-κB and MAPK signaling pathways, and immunomodulatory effects that help prevent the "cytokine storm" associated with severe respiratory distress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yinqiaosan + maxingganshitang.